AEON's ABP-450 Shows Promising Biosimilarity to BOTOX in Stress Tests
Event summary
- AEON Biopharma's ABP-450 demonstrated comparable degradation rates to BOTOX under thermal and oxidative stress conditions.
- Pilot study results support the planned multi-lot comparability study expected to begin in early 2027.
- AEON aims to submit a 351(k) BLA for ABP-450, targeting full-label U.S. market entry.
- The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually.
The big picture
AEON's positive pilot study results strengthen its biosimilarity case for ABP-450, a potential competitor to BOTOX in the lucrative U.S. neurotoxin market. The company's strategy hinges on a totality-of-the-evidence approach to secure FDA approval, with forced degradation data adding a critical layer of analytical support. Success could position AEON as a key player in a market dominated by established brands.
What we're watching
- Regulatory Pathway
- Whether AEON's planned multi-lot comparability study will meet FDA's equivalence criteria for biosimilar approval.
- Market Dynamics
- The pace at which AEON can capture market share in the $3.0 billion U.S. therapeutic neurotoxin market.
- Execution Risk
- How AEON will manage dependencies on Daewoong Pharmaceutical for ABP-450 manufacturing.